Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 5/2016

01-05-2016 | Neuro-oncology (R Soffietti, Section Editor)

Neurocognitive Deficits and Neurocognitive Rehabilitation in Adult Brain Tumors

Authors: Julia Day, BSc (Hons), MScR, David C. Gillespie, MA (Hons), ClinPsyD, PhD, MSc (Fam Therapy), CPsychol, Alasdair G. Rooney, MBChB, MD, Helen J. Bulbeck, PhD, Karolis Zienius, MBChB, BSc, Florien Boele, PhD, Robin Grant, MBChB, MD

Published in: Current Treatment Options in Neurology | Issue 5/2016

Login to get access

Opinion statement

Neurocognitive deficits are common with brain tumors. If assessed at presentation using detailed neurocognitive tests, problems are detected in 80 % of cases. Neurocognition may be affected by the tumor, its treatment, associated medication, mood, fatigue, and insomnia. Interpretation of neurocognitive problems should be considered in the context of these factors. Early post-operative neurocognitive rehabilitation for brain tumor patients will produce rehabilitation outcomes (e.g., quality of life, improved physical function, subjective neurocognition) equivalent to stroke, multiple sclerosis, and head injury, but the effect size and duration of benefit needs further research. In stable patients treated with radiotherapy +/− chemotherapy, the most frequent causes of distress include neurocognitive problems, psychological factors of anxiety, depression, fatigue, and sleep. Exercise, neurocognitive training, neurocognitive behavioral therapy, and medications to treat fatigue, behavior, memory, mood, and removal of drugs that may be associated with neurocognitive side effects (e.g., anti-epileptic drugs) all show promise in helping patients to manage the effects of their neurocognitive impairments better. As these are complex symptoms, multidisciplinary expertise is necessary to evaluate the influence of each variable to plan appropriate support and intervention. Neurocognitive rehabilitation should therefore occur in parallel with disease-centered, medical management from the outset. It should not occur in series, as a restricted phase in a patient’s pathway. It should be considered in the pre- and post-operative period where there are good prospects of recovery, as one would for any brain-injured patient, so that the person may reach their optimal physical, sensory, intellectual, psychological, and social functional level. Yet the identification and selection of patients for early neurological rehabilitation and routine evaluation of cognition is uncommon in neurosurgical wards.
Literature
1.
Lehmann J, De Lisa J, Warren C. Cancer rehabilitation assessment of need development and education of a model of care. Arch Phys Med Rehabil. 1978;59:410–9.PubMed
2.
Grant R. Overview: brain tumour diagnosis and management/Royal College of Physicians guidelines. J Neurol Neurosurg Psychiatry. 2004;75:18–23.CrossRef
3.
4.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef
5.
Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241–5.PubMedPubMedCentral
6.••
Wade D. Rehabilitation—a new approach. Overview and part one: the problems. Clin Rehabil. 2015;29(11):1041–50. This paper emphasizes the importance of early rehabilitation following brain injury for any cause.PubMedCrossRef
7.
Lidstone V, Butters E, Seed PT, Sinnott C, Beynon T, Richards M. Symptoms and concerns among cancer outpatients: identifying the need for specialist palliative care. Palliat Med. 2003;17:588–95.PubMedCrossRef
8.
Mukand JA, Blackinton DD, Crincoli MG, Lee JJ, Santos BB. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil. 2001;80(5):346–50.PubMedCrossRef
9.
Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.PubMedCrossRef
10.
Chang EL, Wefel JS, Hess KR, Allen PK, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10:1037–44.PubMedCrossRef
11.
Gondi V, Mehta MP, Pugh S. Memory preservation with conformal avoidance of the hippocampus during whole brain radiotherapy for patients with brain metastases: primary endpoint results of RTOG 0933. Int J Radiat Oncol Biol Phys. 2013;87(5):1186.CrossRef
12.
Welzel G, Fleckenstein K, Schaefer J, Hermann B, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys. 2008;72:1311–8.PubMedCrossRef
13.
Catt S, Chalmers A, Critchley G, Fallowfield L. Supportive follow up in patients treated with radical intent for high grade glioma. CNS Oncol. 2012;1(1):39–48.PubMedCrossRef
14.••
Kerrigan S, Erridge S, Liaquat I, Graham C, Grant R. Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study. Neurology. 2014;83(6):537–41. This paper examines the relationship between capacity to give consent for surgery and cognitive testing and the value of the verbal fluency test (animals) in identifying patients that require more detailed assessment.PubMedCrossRef
15.
Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al. Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments. Neuro-Oncology. 2013;15(1):122–9.PubMedPubMedCentralCrossRef
16.
Kerrigan S, Rooney A, Grant R. Measuring cognitive function in people with brain tumours using the Addenbrooke’s cognitive examination. J Neurol Neurosurg Psychiatry. 2012;83:1.CrossRef
17.
Davie GL, Hutcheson KA, Barringer DA. Aphasia in patients after brain tumor resection. Aphasiology. 2009;23(9):1196–206.CrossRef
18.
Finch E, Copland DA. Language outcomes following neurosurgery for brain tumours: a systematic review. NeuroRehabilitation. 2014;34:499–514.PubMed
19.
Satoer D, Visch-Brink E, Smits M, Kloet A, Looman C, Dirven C, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. J Neurooncol. 2014;116:153–60.PubMedCrossRef
20.
Racine AC, Li J, Molinaro A, Butowski N, Berger MS. Neurocognitive function in newly diagnosed low-grade glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery. 2015;77(3):371–9.PubMedCrossRef
21.
22.
Klein M, Taphoorn MJB, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high grade glioma patients. J Clin Oncol. 2001;19(20):4037–47.PubMed
23.
Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47:1396–402.PubMedCrossRef
24.••
Rooney AG, Brown PD, Reijneveld JC, et al. Depression in glioma: a primer for clinicians and researchers. J Neurol Neurosurg Psychiatry. 2014;85:230–5. This paper summarises the potential role of depression and antidepressants in glioma and effects on neurorehabilitation.PubMedCrossRef
25.
Folstein M, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRef
26.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.PubMedCrossRef
27.
Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology. 2000;55:1613–20.PubMedCrossRef
28.
Brown PD, Buckner JC, O’Fallon JR, Iturria NL, O’Neill BP, Brown CA, et al. Importance of baseline Mini-Mental State Examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004;59:117–25.PubMedCrossRef
29.
Meyers CA, Wefel JS. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts or sensitivity. J Clin Oncol. 2003;21:3557–8.PubMedCrossRef
30.
31.
Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psycho-Oncology. 2016. doi:10.​1002/​pon.​4046.
32.
Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonize studies of cognitive function in patients with cancer. Lancet Oncol. 2001;12:703–8.CrossRef
33.
Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: therapy and clinical interpretation. Tucson: Neuropsychological Press; 1985.
34.
Benedict RHB, Schretien D, Groninger L, Brandt J. Hopkins Verbal Learning Test—revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43–55.CrossRef
35.
Benton AL, Hannay HJ, Varney NR. Visual perception of line direction in patients with unilateral brain disease. Neurology. 1975;25:907–10.PubMedCrossRef
36.
Benton AL, Hamsher K. Multilingual Aphasia examination. Iowa City: AJA Associates; 1989.
37.
Wechsler D. Wechsler adult intelligence scale – revised. San Antonia: The Psychological Corporation; 1981.
38.
Stewart AL, Ware JE. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University; 1992.
39.••
Gehring K, Sitskoorn MM, Gundy CM, Sikkes SAM, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27:3712–22. This paper emphasizes the importance of cognitive rehabilitation in selected patients post treatment and evidence of longer term benefits.PubMedCrossRef
40.
Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al. Compromised health-related quality of life in patients with low grade glioma. J Clin Oncol. 2011;29:4430–5.PubMedCrossRef
41.
Gehring K, Taphoorn MJ, Sitskoon MM, Aaronson NK. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. Neuro-Oncol Pract. 2015;2:20–31.CrossRef
42.
Fox SW, Lyon D, Farace E. Symptom clusters in patients with highgrade glioma. J Nurs Scholarsh. 2007;39:61–7.PubMedCrossRef
43.
Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum. 1999;26:921–5.PubMed
44.
Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57:41–9.PubMedCrossRef
45.
Powell C, Guerrero D, Sardell S, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: a prospective study. Radiother Oncol. 2011;100:131–6.PubMedCrossRef
46.
Struik K, Klein M, Heimans JJ, Gielissen MF, et al. Fatigue in low-grade glioma. J Neuro-Oncol. 2009;92(1):73–8.CrossRef
47.
Taphoorn MJ, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48–54.PubMedCrossRef
48.
Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer. 2001;92(6):1694–8.PubMedCrossRef
49.
Butler Jr JM, Case LD, Atkins J, Frizzel B, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumour patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69:1496–501.PubMedCrossRef
50.
Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013;15(10):1420–8.PubMedPubMedCentralCrossRef
51.
Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive benefits in patients with cancer. Expert Rev Anticancer Ther. 2012;12(2):255–69.PubMedCrossRef
52.
Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707–15.PubMed
53.
Rooney A, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst. 2010;103:1–16.
54.
Joyce PR. Epidemiology of mood disorders. In: MG Gelder et al., eds. New Oxford Textbook of Psychiatry, 2nd ed. New York: Oxford University Press. Ch 4.5.4; 2000
55.
Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med. 2012;366:1310–8.PubMedCrossRef
56.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRef
57.
58.
National Institute for Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23). London: National Institute for Health and Clinical Excellence; 2009.
59.
Rooney A, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev. 2013;31(5):1–19.
60.
Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;4:1–92.
61.
Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015; Issue 6. Art
62.
Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) Summary Basis of Approval reports. Biol Psychiatry. 2007;62:345–54.PubMedCrossRef
63.
Hesdorffer DC, Hauser WA, Olafsson E, et al. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006;59:35–41.PubMedCrossRef
64.
National Institute for Clinical Excellence (NICE). Depression in adults with a chronic physical health problem: treatment and management. London: National Institute for Health and Clinical Excellence; 2009.
65.
Angst J. Course and prognosis of mood disorders. In: Gelder MG et al., editors. New Oxford textbook of psychiatry. 2nd ed. New York: Oxford University Press; 2009.
66.
Rooney AG, McNamara S, Mackinnon M, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol. 2011;29:4307–12.PubMedCrossRef
67.
Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P. Insomnia among brain tumor patients: a population-based prospective study of tumor patients in Northern Finland. J Psychosoc Oncol. 2013;31(5):507–16.PubMedCrossRef
68.
Mandrell BN, Wise M, Schoumacher RA, Pritchard M, et al. Excessive daytime sleepiness and sleep-disordered breathing disturbances in survivors of childhood central nervous system tumors. Pediatr Blood Cancer. 2012;58:746–51.PubMedPubMedCentralCrossRef
69.
Harjani RR, Janaki MG, Krishnaswamy UM, Alva RC, Ponni A, et al. Epworth sleepiness scale—a novel tool to assess somnolence syndrome post radiotherapy to brain. Int J Cancer Ther Oncol. 2015;3(1):1–4.
70.
Verberne LM, Maurice-Stam H, Grootenhuis MA, Santen H, Van Meeteren AYN. Sleep disorders in children after treatment for a CNS tumour. J Sleep Res. 2012;21:461–9.PubMedCrossRef
71.
Kaleyias J, Manley P, Kothare SV. (2012). Sleep disorders in children with cancer, vol 19. Seminars in Pediatric Neurology. Elsevier
72.
Waltel LM, Nixon GM, Davey MJ, Downie PA, Horne RSC. Sleep and fatigue in pediatric oncology: a review of the literature. Sleep Med Rev. 2015;24:71–82.CrossRef
73.
Provini F, Lombardi C, Lugaresi E. Insomnia in neurological diseases. Semin Neurol. 2005;25:81–9.PubMedCrossRef
74.••
Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro-Oncology. 2012;14:65–72. This paper emphasizes practical strategies that may help patients improve fatigue levels and thus improve engagement with cognitive rehabilitation.
75.
Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.PubMedPubMedCentral
76.
Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum. 2009;36(4):165–77.CrossRef
77.
Muller HL, Handwerker G, Wollny B, Faldum A, Sorensen N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocinol Metab. 2006;87:3993–6.CrossRef
78.
Han EY, Chun MH, Kim BR, Kim HJ. Functional improvement after 4-week rehabilitation therapy and effects of attention deficit in brain tumour patients: comparison with subacute stroke patients. Ann Rehabil Med. 2015;39(4):560–9.PubMedPubMedCentralCrossRef
79.
Zucchella C, Capone A, Codella V, De Nunzio AM, et al. Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial. J Neuro- Oncol. 2013;114(1):93–100.CrossRef
80.
Butler J, Rapp S, Shaw E. Managing the cognitive effects of brain tumour radiation therapy. Curr Treat Options in Oncol. 2006;7(6):517–23.CrossRef
81.
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, et al. Clinical course and progression-free survival of adult intracranial and spinal epedymoma patients. Neuro Oncol. 2015;17(3):440–7.PubMedPubMedCentral
82.••
Khan F, Amatya B, Ng L, Drummond K, Galea M. Multidisciplinary rehabilitation after primary brain tumour treatment. Cochrane Database Syst Rev. 2015;8:1–49. This is a high quality systematic review of neuro-rehabilitation in patients with brain tumours.
83.
Khan F, Amatya B, Drummon K, Galea M. Effectiveness of integrated multidisciplinary rehabilitation in primary brain cancer survivors in an Australian community cohort: a controlled clinical trial. J Rehabil Med. 2014;46:754–60.PubMedCrossRef
84.
Piil K, Juhler M, Jakobsen J, Jarden M. Controlled rehabilitative and supportive care intervention trials in patients with high grade gliomas and their caregivers: a systematic review. BMJ Supportive & Palliative Care. 2014; 0:1–8.
85.
Day J, Zienius K, Gehring K, Grosshans D, Taphoorn M, Grant R, et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev. 2014;12:1–62.
86.
Locke D, Cerhan J, Wu W, Malec J, Clark M, Rummans T, et al. Cognitive rehabilitation and problem solving to improve quality of life of patients with primary brain tumors: a pilot study. J Support Oncol. 2008;6(8):383–91.PubMed
87.
Brown PD, Pugh S, Laack NN, Wefel JS, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429–37.PubMedPubMedCentralCrossRef
88.
Malak A, Diramali A, Yucesoy K. Effects of counselling on some care outcomes among patients with a brain tumor: pain, seizure, constipation, infection, dispatch conditions. Neuro Oncol. 2010;6(2):25–31.
89.
Cavers D, Hacking B, Erridge SE, Kendall M, Morris PG & Murray SA. Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study. CMAJ. 2012;184(7):E373–82. doi:10.​1503/​cmaj.​111622.
90.
91.
Cashman R, Bernstein L, Bilodeau D, Bovett G, Jackson B, Yousefi M, et al. Evaluation of an educational program for the caregivers of persons diagnosed with a malignant glioma. Can Oncol Nurs J. 2007;17(1):6–15.PubMedCrossRef
92.
Flechl B, Marosi C. Austrian patients with glioblastoma multiforme and their families: socioeconomic aspects. Eur Assoc Neuro-Oncol Mag. 2013;3(2):46–8.
93.
94.
Bartolo M, Zucchella C, Pace A, Lanzetta G, et al. Early rehabilitation after surgery improves functional outcome in inpatients with brain tumors. J Neurooncol. 2012;107:537–44.PubMedCrossRef
95.
Boele F, Hoeben W, Hilverda K, Lenting J, Calis A, Sizoo E, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma patients: a randomised controlled trial. J Neurooncol. 2013;111(3):303–11.PubMedCrossRef
96.
Rosenberg A, Dussel V, Kang T, Geyer J, Gerhardt C, Feudtner C, et al. Psychological distress in parents of children with advanced cancer. JAMA Paediatr. 2013;167(6):537–43.CrossRef
Metadata
Title
Neurocognitive Deficits and Neurocognitive Rehabilitation in Adult Brain Tumors
Authors
Julia Day, BSc (Hons), MScR
David C. Gillespie, MA (Hons), ClinPsyD, PhD, MSc (Fam Therapy), CPsychol
Alasdair G. Rooney, MBChB, MD
Helen J. Bulbeck, PhD
Karolis Zienius, MBChB, BSc
Florien Boele, PhD
Robin Grant, MBChB, MD
Publication date
01-05-2016
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 5/2016
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-016-0406-5

Other articles of this Issue 5/2016

Current Treatment Options in Neurology 5/2016 Go to the issue

Movement Disorders (A Videnovich, Section Editor)

Myoclonus: Pathophysiology and Treatment Options

Cerebrovascular Disorders (HP Adams, Section Editor)

Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy

Sleep Disorders (A Iranzo, Section Editor)

Sleep-Related Epilepsy

Neurologic Manifestations of Systemic Disease (N Scolding and C Rice, Section Editors)

Behçet’s Disease and Nervous System Involvement